|
|
Immunitybio inc (NASDAQ: IBRX) |
|
|
|
| |
Immunitybio Inc's Customers Performance
IBRX
| |
|
IBRX's Source of Revenues |
During the corresponding time, Immunitybio Inc recorded a revenue increase by 41192.5 % year on year, sequentially revenue grew by 118.71 %. While revenue at the Immunitybio Inc 's corporate clients
• List of IBRX Customers
|
|
|
for the same period Immunitybio Inc recorded revenue increase by 41192.5 % year on year, sequentially revenue grew by 118.71 %.
• List of IBRX Customers
| |
| Product revenue net |
|
 99.95 % |
of total Revenue |
| Other revenues |
|
0.05 % |
of total Revenue |
| Reportable Segment |
|
100 % |
of total Revenue |
| U S |
|
100 % |
of total Revenue |
|
Select the Relationship:
|
|
Select the Category:
|
|
Immunitybio Inc's Comment on Sales, Marketing and Customers
News about Immunitybio inc Contracts |
ImmunityBio, Inc. a prominent player in the field of immunotherapy, has recently achieved key designations and made substantial advancements that may reshape treatment paradigms for patients suffering from pancreatic cancer and complications associated with chemotherapy and radiotherapy. The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for its products ANKTIVA and CAR-NK (PD-L1 t-haNK), marking a significant milestone for the company and for the immunotherapy landscape. This article delves into the implications of these advancements, the importance of novel coding for reimbursement, and the promising clinical outcomes from ongoing trials. Regen...
|
Recently, ImmunityBio, Inc. has announced the assignment of a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for its innovative immunotherapy, ANKTIVA (nogapendekin alfa inbakicept-pmln). Effective January 1, 2025, this J-code facilitates easier reimbursement and broader access to this groundbreaking therapy for adult patients with Bacillus Calmette-Gu�rin (BCG)-unresponsive cancers. In this article, we delve into the implications of this development on the landscape of uro-oncology, the clinical efficacy of ANKTIVA, and a future trajectory for immunotherapy in oncology. Immunotherapy represents a paradigm shift in the treatment of various malignancies, with recent advancements enhancing...
|
ImmunityBio, a biopharmaceutical company, has made significant progress in the field of immunotherapy with the administration of ANKTIVA (nogapendekin alfa inbakicept-pmln) to multiple patients in the United States. This immunotherapy has been designed to target Bacillus Calmette-Gurin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ. Following its recent approval by the U.S. Food and Drug Administration (FDA), ANKTIVA is set to revolutionize the treatment of this challenging cancer type.Insurance Coverage and Prompt Administration of ANKTIVA:ImmunityBio has accomplished a major feat by securing insurance coverage for ANKTIVA therapy across multiple states. This achievement ens...
|
Intro: ImmunityBio, a biotechnology company known for its groundbreaking research in cancer immunotherapy, recently made significant announcements regarding its upcoming Annual Meeting of Stockholders and advancements in bladder cancer research. With the approval of their innovative treatment, ANKTIVA, ImmunityBio continues to make strides in the field of non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) treatment. In this article, we will delve into the details shared by the company s Chief Executive Officer and Executive Chairman, Dr. Patrick Soon-Shiong, shedding light on these significant developments.The 2024 Annual Meeting of Stockholders: ImmunityBio has scheduled its 2024 Annual Meet...
|
Biopharmaceutical company ImmunityBio, Inc. (NASDAQ: IBRX) has recently announced that its 2024 Annual Meeting of Stockholders will take place on June 11, 2024, at 9:30 a.m. Pacific Time. The meeting will be conducted in a virtual-only format, without a physical location due to ongoing uncertainties surrounding the COVID-19 pandemic. Stockholders holding shares as of April 17, 2024, will be eligible to vote and participate in the Annual Meeting.Details of the Virtual Annual Meeting:The decision to hold the Annual Meeting in a virtual format aligns with ImmunityBio s commitment to prioritize the health and safety of its shareholders and employees. By conducting the meeting online, attendees will have the oppo...
|
In a recent series of podcasts conducted by UroToday, ImmunityBio, Inc. reveals groundbreaking developments in the field of bladder cancer research ...
|
ImmunityBio, a leading biotechnology company based in Culver City, California, has recently inked an exclusive global arrangement with the esteemed Serum Institute of India. This groundbreaking partnership aims to revolutionize cancer treatment by combining the expertise of ImmunityBio and the unparalleled manufacturing capabilities of Serum Institute, widely regarded as the world s largest producer of vaccines.The agreement specifically focuses on the supply of Bacillus Calmette-Guerin (BCG), a vaccine with immense potential in treating various types of cancer. Under this alliance, Serum Institute will manufacture the standard BCG (sBCG) currently approved for use outside the United States. Additionally, th...
|
N-803 Combined with Neutralizing Antibodies Shows Promise in HIV Viral Control: A Potential Breakthrough in Antiretroviral TherapyIn a recent publication in the online issue of Science, First Release, ImmunityBio, a clinical-stage immunotherapy company, announced positive preclinical data that suggests combination therapy with N-803, an IL-15 superagonist, and broadly neutralizing antibodies may enable the immune system to manage human immunodeficiency virus (HIV) without the need for antiretroviral treatment. This groundbreaking research opens up new possibilities in the field of HIV therapy and potentially offers a more sustainable approach to viral control.Study 1: N-803 and Broadly Neutralizing Antibodie...
|
In a significant development in the oncology world, ImmunityBio, Inc. - a clinical-stage immunotherapy company, disclosed that the quality-of-life study conducted in BCG-unresponsive bladder cancer trail has illustrated tangible improvement in the physical function of cancer patients. The ground-breaking study demonstrates a favorable risk-benefit ratio for N-803 Plus BCG, further bolstering the hopes for a breakthrough in effective bladder cancer treatment.The findings were part of the Patient-Reported Outcomes (PROs) from the phase 2/3 QUILT 3.032 study of N-803 plus BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). This research has been published in the peer-reviewed journal, Urology Pr...
|
IBRX's vs. Customers, Data
(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)
| COMPANY NAME |
MARKET CAP |
REVENUES |
INCOME |
EMPLOYEES |
| Immunitybio inc |
2,158.50 |
31.22 |
-409.18 |
202 |
| SUBTOTAL |
0.00 |
0.00 |
0.00 |
- |
|
